Results 251 to 260 of about 146,010 (350)

Dual cholinergic modulation in dementia: Quinuclidine carbamates targeting butyrylcholinesterase and α7 nicotinic receptor

open access: hybrid
Peter Mastnak-Sokolov   +15 more
openalex   +1 more source

Gut proteome and microbiome alterations: Analysis of transverse colon samples from pathologically confirmed Alzheimer's disease patients

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) has been regarded as a brain‐first disorder. Emerging evidence suggests that the gut may influence central nervous system pathology, but the mechanisms remain unclear. METHODS We conducted a proteomic and microbial analysis of transverse colon samples from clinically and pathologically confirmed AD and ...
Qiwen Cheng   +6 more
wiley   +1 more source

Relationship of cholinergic basal forebrain atrophy with the time course of Alzheimer's disease pathology and cognitive decline in adults with Down syndrome: a longitudinal cohort study

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Adults with Down syndrome (DS) display increased Alzheimer's disease (AD) risk. The cholinergic system declines early in the AD continuum and relates to cognitive and functional decline. We aimed to identify the timeline of cholinergic decline in relation to hippocampal atrophy within the AT(N) framework in DS.
Jason K. Russell   +7 more
wiley   +1 more source

Cholinergic system in patients with chronic kidney disease: cognitive and renal implications. [PDF]

open access: yesNephrol Dial Transplant
Xu H   +13 more
europepmc   +1 more source

Heartfelt intervention: A role for PVN oxytocin neurons in the prediabetic heart

open access: yes
The Journal of Physiology, EarlyView.
Grace K. Nielsen   +2 more
wiley   +1 more source

Six‐month follow‐up of ARIA‐H and iron deposition in real‐world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION With the approval of lecanemab for treating Alzheimer's disease (AD), there is an urgent need to evaluate its safety and treatment effects on biomarkers in real‐world practice. METHODS Patients receiving lecanemab (n = 72) underwent routine 3T and 7T magnetic resonance imaging (MRI) for amyloid‐related imaging abnormality (ARIA ...
Weiwei Zhang   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy